Brain Cancer Clinical Trials in Texas

Showing 41-60 of 148 trials

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Cervical CancerColorectal CancerEsophageal Cancer+16 more

Telix Pharmaceuticals (Innovations) Pty Ltd11 participantsStarted Jun 2023

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +7 more locations

TERMINATEDPhase 2126 miles

VB-111 in Surgically Accessible Recurrent/Progressive GBM

NCT04406272

This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

GlioblastomaRecurrent Glioblastoma

Dana-Farber Cancer Institute15 participantsStarted Aug 2020

Los Angeles, California, United States • Boston, Massachusetts, United States • San Antonio, Texas, United States +1 more locations

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Brain Cancer Trials in Other Cities

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Tempus Priority Study: A Pan-tumor Observational Study

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

A Study of Abemaciclib in Recurrent Glioblastoma

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Other Conditions in Texas